Literature DB >> 33090396

CircRNA ZFR stimulates the proliferation of hepatocellular carcinoma through upregulating MAP2K1.

B C Cedric1, T D M Souraka, Y-L Feng, P Kisembo, J-C Tu.   

Abstract

OBJECTIVE: The aim of the study was to illustrate the function of circRNA ZFR in aggravating the development of hepatocellular carcinoma (HCC) by upregulating MAP2K1. PATIENTS AND METHODS: CircRNA ZFR levels in 62 paired HCC and paracancerous species were detected. The influence of circRNA ZFR on clinical data of HCC patients was analyzed. After the overexpression or knockdown of circRNA ZFR, changes in viability and clonality of Bel-7402 and Hep3B cells were assessed, respectively. The involvement of circRNA ZFR/MAP2K1 axis in the development of HCC was explored through Luciferase assay and rescue experiments.
RESULTS: CircRNA ZFR was highly expressed in HCC species than the paracancerous ones. Higher level of circRNA ZFR predicted more advanced tumor grading of HCC. The knockdown of circRNA ZFR attenuated the proliferative ability of HCC cells, while the overexpression of circRNA ZFR obtained opposite results. MAP2K1 level was positively correlated to that of circRNA ZFR. Luciferase assay uncovered that circRNA ZFR can be targeted by MAP2K1 through specific binding sites. In addition, the overexpression of MAP2K1 could reverse the influence of silenced circRNA ZFR on proliferative ability of HCC cells.
CONCLUSIONS: CircRNA ZFR is upregulated in HCC and closely linked to tumor grading. It promotes proliferative ability in HCC by upregulating MAP2K1.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33090396     DOI: 10.26355/eurrev_202010_23203

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  5 in total

1.  CircSOD2 Contributes to Tumor Progression, Immune Evasion and Anti-PD-1 Resistance in Hepatocellular Carcinoma by Targeting miR-497-5p/ANXA11 Axis.

Authors:  Rong Ye; Xingyu Lu; Jianping Liu; Qing Duan; Junqi Xiao; Xunhong Duan; Zhibiao Yue; Fengen Liu
Journal:  Biochem Genet       Date:  2022-08-25       Impact factor: 2.220

2.  Magnetically responsive nanoplatform targeting circRNA circ_0058051 inhibits hepatocellular carcinoma progression.

Authors:  Song You; Zijin Luo; Niangmei Cheng; Ming Wu; Yongping Lai; Fei Wang; Xiaoyuan Zheng; Yingchao Wang; Xiaolong Liu; Jingfeng Liu; Bixing Zhao
Journal:  Drug Deliv Transl Res       Date:  2022-09-16       Impact factor: 5.671

Review 3.  Circular RNAs in hepatocellular carcinoma: Recent advances.

Authors:  Zhao-Shan Niu; Wen-Hong Wang
Journal:  World J Gastrointest Oncol       Date:  2022-06-15

4.  Prognostic and clinicopathologic significance of circZFR in multiple human cancers.

Authors:  Zhongyue Liu; Wenchao Zhang; Chao Tu; Wenyi Li; Lin Qi; Zhiming Zhang; Lu Wan; Zhimin Yang; Xiaolei Ren; Zhihong Li
Journal:  World J Surg Oncol       Date:  2022-08-26       Impact factor: 3.253

Review 5.  Current Molecular Biology and Therapeutic Strategy Status and Prospects for circRNAs in HBV-Associated Hepatocellular Carcinoma.

Authors:  Rui Liao; Lei Liu; Jian Zhou; Xufu Wei; Ping Huang
Journal:  Front Oncol       Date:  2021-07-02       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.